ChiMed Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients

Chi-Med Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients

Hutchison China MediTech (Chi-Med) has started a China Phase I trial of its novel spleen tyrosine kinase (Syk) inhibitor as a first line treatment in elderly patients with acute myeloid leukemia. The molecule, HMPL-523, will be administered in combination with an approved nucleoside metabolic inhibitor. In September, Chi-Med's lead drug, Elunate® (fruquintinib), was approved in China as a third-line treatment for metastatic colorectal cancer, the first China-developed drug approved for a cancer indication. More details....

Stock Symbol: (AIM/NSDQ: HCM)

Share this with colleagues:

More From BioPortfolio on "Chi-Med Starts China Trials of Syk Inhibitor in Acute Myeloid Leukemia Patients"